Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1804-1810

  Von Lintig, Friederike C ^a,c   Huvar, Ivana ^a,c   Law, Ping ^a,c   Diccianni, Mitchell B ^b,c   Yu, Alice L ^b,c   Boss, Gerry R ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW CELL; CANCER INVASION; CHILD; CHILDHOOD LEUKEMIA; FEMALE; GENE ACTIVATION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; INFANT; LEUKOCYTE; LYMPHOCYTE; MALE; ONCOGENE RAS; PRIORITY JOURNAL;

ADOLESCENT; BLOOD CELLS; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, T-CELL, ACUTE; LEUKOCYTES; LYMPHOCYTES; MALE; RAS PROTEINS;

EID: 0034027104     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Barbacid, M. Ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
2. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. F., and Der, C. J. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998.
3. Bos, J. L. ras-Oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
4. Senn, H.-P., Tran-Thang, C., Wodnar-Filipowicz, A., Jiricny, J., Fopp, M., Gratwohl, A., Signer, E., Weber, W., and Moroni, C. Mutation analysis of the N-ras proto-oncogene in active and remission phase of human acute leukemias. Int. J. Cancer, 41: 59-64, 1988.
5. Neri, A., Knowles, D. M., Greco, A., McCormick, F., and Dalla-Favera, R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA, 85: 9268-9272, 1988.
6. Lubbert, M., Mirro, J. Jr., Miller, C. W., Kahan, J., Issac, G., Kitchingman, G., Mertelsmann, R., Herrmann, F., McCormick, F., and Koeffler, H. P. N-Ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood, 75: 1163-1169, 1990.
7. Rodenhuis, S., Bos, J. L., Slater, R. M., Behrendt, H., Van't Veer, M., and Smets, L. A. Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood, 67: 1698-1704, 1986.
8. Prigent, S. A., Nagane, M., Lin, H., Huvar, I., Boss, G. R., Feramisco, J. R., Cavenee, W. K., and Su Huang, H.-J. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated EGF receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol. Chem., 271: 25639-25645, 1996.
9. Basu, T., and et al. Aberrant regulation of Ras proteins in malignant tumour cells from typel neurofibromatosis patients. Nature (Lond.), 356: 713-715, 1992.
10. Scheele, J. S., Rhee, J. M., and Boss, G. R. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: Comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 1097-1100, 1995.
11. Guha, A., Lau, N., Huvar, I., Gutmann, D., Provias, J., Pawson, T., and Boss, G. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene, 12: 507-513, 1996.
12. Guha, A., Feldkamp, M., Lau, N., Huvar, I., Boss., G., and Pawson, T. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene, 15: 2755-2765, 1997.
13. Satoh, T., Nakafuku, M., Miyahima, A., and Kaziro, Y. Involvement of ras protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc. Natl. Acad. Sci. USA, 88: 3314-3318, 1991.
14. Turner, B., Rapp, U., App, H., Greene, M., Dobashi, K., and Reed, J. Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line. Proc. Natl. Acad. Sci. USA, 88: 1227-1231, 1991.
15. shc in T lymphocytes. J. Biol. Chem., 24: 17659-17661, 1993.
16. Franklin, R. A., Tordai, A., Patel, H., Gardner, A. M., Johnson, G. L., and Gelfand, E. W. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J. Clin. Invest., 93: 2134-2140, 1994.
17. Nel, A. E., Gupta, S., Lee, L., Ledbetter, J. A., and Kanner, S. B. Ligation of the T-cell antigen receptor (TCR) induces association of hSos1, ZAP-70, phospholipase C-t1, and other phosphoproteins with Grb2 and the zeta-chain of the TCR. J. Biol. Chem., 31: 18428-18436, 1995.
18. ras1. J. Immunol., 151: 4513-4522, 1993.
19. Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
20. Alessi, D., Cuenda, A., Cohen, P., Dudley, D., and Saltiel, A. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J. Biol. Chem., 270: 27489-27494, 1995.
21. Boss, G. R., Thompson, L. F., Spiegelberg, H. L., Pichler, W. J., and Seegmiller, J. E. Age-dependency of lymphocyte ecto-5′-nucleotidase activity. J. Immunol., 125: 679-682, 1980.
22. Hattori, S., Clanton, D. J., Satoh, T., Nakamura, S., Kaziro, Y., Kawakita, M., and Shih, T. Y. Neutralizing monoclonal antibody against ras oncogene product p21 which impairs guanine nucleotide exchange. Mol. Cell. Biol., 7: 1999-2002, 1987.
23. Suhasini, M., Li, H., Lohmann, S. M., Boss, G. R., and Pilz, R. B. Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway. Mol. Cell. Biol., 18: 6983-6994, 1998.
24. Sharma, P. M., Egawa, K., Huang, Y., Martin, J. L., Huvar, I., Boss, G. R., and Olefsky, J. M. Inhibition of phosphatidylinositol 3-kinase activity by adenovirus-mediated gene transfer and its effect on insulin action. J. Biol. Chem., 273: 18528-18537, 1998.
25. Pilz, R. B., Huvar, I., Scheele, J. S., Van den Berghe, G., and Boss, G. R. A decrease in the intracellular guanosine 5′-triphosphate concentration is necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a charge in the activation state of Ras, the transforming principle of HL-60 cells. Cell Growth Differ., 8: 53-59, 1997.
26. Brunk, C., Jones, K., and James, T. Assay for nanogram quantities of DNA in cellular homogenates. Anal. Biochem., 92: 497-500, 1979.
27. Porter, A. C., and Vaillancourt, R. R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene, 16: 1343-1352, 1998.
28. Bar-Sagi, D., and Feramisco, J. R. Microinjection of the ras oncogene protein into PC 12 cells induces morphological differentiation. Cell, 42: 841-848, 1985.
29. ras/MAP kinase signaling pathway. Blood, 83: 949-957, 1994.
30. Daeipour, M., Kumar, G., Amaral, M. C., and NelI, A. E. Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. J. Immunol., 150: 4743-4753, 1993.
31. Okuda, K., Sanghera, J. S., Pelech, S. L., Kanakura, Y., Hallek, M., Griffin, J. D., and Druker, B. J. Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood, 79: 2880-2887, 1992.
32. Damen, J. E., Liu, L., Cutler, R. L., and Krystal, G. Erythropoietin stimulates the tyrosine phosphorylation of She and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein. Blood, 82: 2296-2303, 1993.
33. BCR/ABL. J. Biol. Chem., 7: 5016-5021, 1994.
34. Welham, M. J., Duronio, V., Leslie, K. B., Bowtell, D., and Schrader, J. W. Multiple hemopoietins, with the exception of Interleukin-4, induce modification of She and mSos1, but not their translocation. J. Biol. Chem., 209: 21165-21176, 1994.
35. Satoh, T., Endo, M., Nakafuku, M., Nakamura, S., and Kaziro, Y. Accumulation of p21rasGTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc. Natl. Acad. Sci. USA, 87: 7926-7929, 1990.
36. De Rooij, J., and Bos, J. L. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene, 14: 623-625, 1997.
37. Hamilton, M., and Wolfman, A. Ha-ras, and N-ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene, 16: 1417-1428, 1998.
38. Pui, C.-H., Behm, F. G., and Crist, W. M. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood, 82: 343-362, 1993.
39. Diccianni, M. B., Batova, A., Yu, J., Vu, T., Pullen, J., Amylon, M., Pollock, B. H., and Yu, A. L. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leukemia Res., 21: 549-558, 1997.
40. Oui, C.-H., and Evers, S. G. Acute lymphoblastic leukemia. New Engl. J. Med., 339: 605-615, 1998.
41. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. K. Reovirus therapy of tumors with activated Ras pathway. Science (Washington DC), 282: 1332-1334, 1998.